biotech · Hypertension · Essential Hypertension · QNTM
Quantum Pharmaceuticals
Quantum Biopharma
Quantum Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- volkova 6A-1206, Moscow, 141700, RU, CA
- Founded
- 2004
- Employees
- 29
- Programs
- 18
- Drugs
- 17
- Patents
- 36
Quantum Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Quantum Pharmaceuticals.
Quantum Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Dendritic Cell Vaccination
Quantum Biopharma
Breast Cancer
1 trial -
FSD201
Quantum Biopharma
COVID-19
1 trial -
FSD201
Quantum Biopharma
Mast Cell Activation Syndrome
1 trial -
QGC001
Quantum Biopharma
Essential Hypertension
1 trial -
QGC001
Quantum Biopharma
Heart Failure
1 trial -
QGC001
Quantum Biopharma
Hypertension
1 trial -
Ramipril
Quantum Biopharma
Myocardial Infarction
1 trial
Frequently asked questions
How many clinical projects does Quantum Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.